Home/Pipeline/BEN-2293 / AZD3470

BEN-2293 / AZD3470

Atopic Dermatitis

Phase 2aActive (Partnered)

Key Facts

Indication

Atopic Dermatitis

Phase

Phase 2a

Status

Active (Partnered)

Company

BenevolentAI

About BenevolentAI

BenevolentAI's mission is to transform drug discovery by applying advanced artificial intelligence and machine learning to vast biomedical datasets. Its key achievement is the development of a proprietary, decade-invested knowledge graph and AI platform that generates novel, testable hypotheses for target identification and patient stratification. The company's strategy is dual-pronged: advancing an internal pipeline of drug candidates while securing strategic collaborations with large pharma to validate its platform and generate revenue. It became a publicly traded company on Euronext Amsterdam in 2022.

View full company profile

Therapeutic Areas

Immunology Neurology Inflammatory Diseases

Other Atopic Dermatitis Drugs

Drug	Company	Phase	Status
PEP Biologic™	Intent Biologics	Unknown	Active
HBM7575 (SKB575)	Harbour BioMed	IND Filed	Active (Global)
ITK inhibitor	Acellera	Pre-clinical	Hit-to-Lead
ENS-002 (Fermata Derm)	Concerto Biosciences	Pre-clinical	Active
Lead Program	MatriSys Bioscience	Phase 1	Active
Atopic Dermatitis Trial	Well Pharma Medical Research	Not Specified	Active
MEndoB	Micreos	Pre-clinical	Active
Atopic Dermatitis Program	Lxbio Pharmaceuticals	Pre-clinical	Active
B244	AOBiome	Phase 3	Active
CTO1681	CytoAgents	Pre-clinical	Active
DS107	DS Biopharma	Phase 2	Active
AX-158	Artax Biopharma	Phase 2	Active